Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 907-131-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: EPA TSCA Testing Guidelines (1985; 1987)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 2,2'-(ethylenedioxy)diethanol
- EC Number:
- 203-953-2
- EC Name:
- 2,2'-(ethylenedioxy)diethanol
- Cas Number:
- 112-27-6
- Molecular formula:
- C6H14O4
- IUPAC Name:
- 2,2'-[ethane-1,2-diylbis(oxy)]diethanol
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- purity: > 99%
Test animals
- Species:
- mouse
- Strain:
- CD-1
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Timed-pregnant dams were dosed daily with undiluted TEG or vehicle alone on gestation days 6 - 15. All treatments were administered by gavage. The dose volume was based on the dose group and the individual animals' most recent body weight. The doses employed based on results from a dose range-finding study, also performed on timed-pregnant mice. Vehicle control animals were dosed with deionized water at the top dose volume.
All females on study were weight on g.d. 0, 6, 9, 12, 15 and 18. Food and water consumption were measured at 3-day intervals throughout g.d. 0 - 18. All females were examined daily for clinical signs of toxicity. The treatment period for all study females was g.d. 6 - 15.
The gravid uterus, ovaries (including corpora lutea), cervix, vagina and abdominal and thoracic cavities were examined grossly. Ovarian corpora lutea af pregnancy were counted. Maternal liver and uterine weights were determined. Maternal kidneys were also weighed, and then bisected (left longitudinally, right transversely) and fixed in buffered neutral 10% formalin for possible subsequent histopathologic examination (kidneys from high-dose and control group dams were subsequently examined by light microscopy). The uterus was externally examined for signs of hemorrhage, removed from the abdominal cavity and dissected longitudinally to expose the contents. All live and dead fetuses and resorption sites were noted and recorded. Uteri from females that appeared non-gravid were placed in a 10% ammonium sulfide solution for detection of early resorptions. - Details on mating procedure:
- Mice were mated 1:1 (one male:one female) in stainless steel wire-mesh cages (23.-5 cm:x 20.0 cm x 18 cm high) und the paperboard beneath the cages was checked daily for dropped copulation plugs. Each male was used only once in this study. Successfully mated (plug-positive) females were housed singly in animal room 147 for the duration of the study. The day a dropped copulation plug was found was desigated gestation day (gd) 0. Thirty plug positive females were assigned to each experimental group by a randomization procedure stratified by body weight such that all groups were equivalent in both mean body weight and body weight range on g.d. 0.
- Duration of treatment / exposure:
- gestation day 6 - 15
- Frequency of treatment:
- daily
- Duration of test:
- until g.d. 18
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.5 other: mL/kg bw/day
- Remarks:
- Nominal concentration
- Dose / conc.:
- 5 other: mL/kg bw/day
- Remarks:
- Nominal concentration
- Dose / conc.:
- 10 other: mL/kg bw/day
- Remarks:
- Nominal concentration
- No. of animals per sex per dose:
- Total: 206
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Because of the lack of toxicity observed from a probe study, a dose (11,000 mg/kg) at approximately 11 times the limit test (1000 mg/kg) had to be used to produce maternal and fetal toxicity. At a dose approximately 6 times the limit test, fetal toxicity was observed. It is extremely unlikely that there is any reasonably foreseeable application or use at which humans would be exposed to such high levels of TEG.
Examinations
- Maternal examinations:
- All females an study were weighed on gd 0, 6 (prior to onset of dosing), 9, 12, 15 (during the dosing period) and 18. Food and water consumption were measured at three-day intervals throughout gestation (gd 0-18). All females were examined daily for clinical signs of toxicity. The treatment period for all study females was gd 6 through 15.
- Ovaries and uterine content:
- The gravid uterus, ovaries (including corpora lutea), cervix, vagina and abdominal and thoracic cavities were examined grossly. Ovarian corpara lutea of pregnancy were counted. Maternal uterine weights were determined.
- Fetal examinations:
- All live fetuses were weighed and sexed. All fetuses were examined for external variations and malformations including cleft palate. All live fetuses in each litter were examined for thoracic and abdominal visceral ahnormallties by modification of methods described by Staple (1974). One-half of the live fetuses in each litter were decapitated and their heads ware fixed In Bouin's solution for examination of craniofacial structures by sectioning methods modified from Wilson (1973). All fetuses (50% intact, 50% decapitated) in each litter were eviscerated, fixed In ethanol, processed for skeletal staining with alizarin red S (Crary, 1962; Paltzer and Schareain, 1966), and examined for skeletal malformations and variations.
- Statistics:
- The unit of comparison was the pregnant female or the litter (Weil, 1970).
Results of the quantitative continuous variables (e.g. maternal body weights, organ weights, etc.) were intercompared for the three TEG-exposed groups and the vehicle control group by use of Levene's test for equal variances (Levene, 1960), analysis of variance (ANOVA), and t-tests with Bonferroni probabilities for pairwise comparisons. When Levene's test indicated homogeneous variances and the ANOVA was significant, the pooled t-test was used. When Levene's test indicated heterogeneous variances, all groups were compared by an ANOVA for unequal variances (Brown and Forsythe, 1974) followed, when necessary, by the separate variance t-test.
Nonparametric data obtained following laparohysterectomy were statiatically treated using the Kruskal-Wallis test (Sokal and Rohlf, 1969) followed by the Mann-Whitney U test (Sokal and Rohlf, 1969) when appropriate. Incidence data were compared using Fisher's Exact Test (Sokal and Rohlf, 1969). For all statistical tests, the probability value of p < of 0.05 (two-tailed) was used as the critical level for significance.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Clinical observations of the dams were recorded daily. There were no statistically significant treatment-related clinical signs of toxicity. However, treatment-associated clinical signs were observed in 2 dams at 10.0 mL/kg/day. These included hypoactivity in both dams, and audible and rapid respiration in one dam.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- No females aborted or died prior to scheduled sacrifice. One female, at 10.0 mL/kg/day, delivered early (on g.d. 18), was euthanized, and removed from the study.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Periodic maternal body weights and body weight changes were statistically equivalent across treatment groups. No apparent trends (nonstatistically significant reductians) were observed at any exposure level. There were no treatment-related differences in maternal terminal body weight.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption during gestation expressed as grams/dam/day was statistically equivalent among groups.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- Water consumption was equivalent among groups.
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- While not statistically significant, gravid uterine weight appeared reduced at 5.0 and 10.0 mL/kg/day. Corrected terminal body weight (body weight at sacrifice minus gravid uterine weight), corrected body weight change (gestational weight gain minus gravid uterine weight), liver weight (absolute and relative to corrected body weight) and absolute kidney weight were unaffected by treatment. Relative kidney weight was significantly increased at 10.0 mL/kg/day.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no treatment-related necropsy findings of the dams at scheduled sacrifice on g.d. 18. At 0.5 (but not 5.0 and 10.0) mL/kg/day dams exhibited a statistically increased incidence of cystic ovaries. Findings at 10.0 mL/kg/day involved 2 dams, one exhibiting small kidneys and one exhibiting clotted blood and colour change in a single amniotic sac. These findings were not considered to be treatment-related
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Microscopic evaluation of maternal kidneys from the 0.0 and 10.0 mL/kg/day groups revealed no treatment-related histological changes.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- Percent preimplantation and postimplantation losses were equivalent across groups.
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): effects observed, non-treatment-related
Field "Description (incidence and severity)" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.DescriptionIncidenceAndSeverityEffectsOnPregnancyDuration): One female each at 0.0, 1.0 and 10.0 mL/kg/day and 2 females at 5.0 mL/kg/d contained only non-viable implants (early or late resorptions or dead fetuses) at scheduled sacrifice. A total of 25 - 28 litters containing one or more live fetuses were examined in each group. - Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- Pregnancy rate was equivalent for all dose groups, ranging from 90.0 - 96.7%.
- Other effects:
- no effects observed
- Details on maternal toxic effects:
- There was no effect of treatment on the number of ovarian corpora lutea, total, viable or non-viable (early and late resorptions and dead fetuses) implantations per litter or on sex ratio (percent males).
Effect levels (maternal animals)
- Dose descriptor:
- NOEL
- Effect level:
- 5 other: mL/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- organ weights and organ / body weight ratios
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Fetal body weights (all fetuses, male or female) per litter were significantly reduced at 5.0 and 10.0 mL/kg/day. Fetal body weights per litter at 0.5 mL/kg/day were equivalent to control values.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): effects observed, treatment-related
Field "Description (incidence and severity)" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.DescriptionIncidenceAndSeverityFetalPupBodyWeightChanges): Fetal body weights (all fetuses, male or female) per litter were significantly reduced at 5.0 and 10.0 mL/kg/day. Fetal body weights per litter at 0.5 mL/kg/day were equivalent to control values. - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- There no effect on sex ratio (percent males).
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no statistical differences in the incidences of any individual malformations. A total of 78 different types of individual fetal skeletal variations were observed. Of these, six findings, cervical centra #1, #2, #3 and/or #4 poorly ossified, reduced number of caudal segments, poorly ossified frontal bone, poorly ossified supraoccipital bone, some proximal phalanges of the hindlimb poorly ossified and some proximal phalanges of the hindlimb unossified, exhibited significantly increased incidences at 10.0 mL/kg/day when compared to the control group. There was also a statistically significant increase in the incidence of poorly ossified supraoccipital and frontal at 5.0 mL/kg/day. There were no statistically increased individual skeletal variations at 0.5 mL/kg/day. There were no treatment-related increases in the incidence of variations by category (external, visceral or skeletal) or of total variations.
- Visceral malformations:
- no effects observed
- Other effects:
- no effects observed
Effect levels (fetuses)
- Dose descriptor:
- NOEL
- Effect level:
- 0.5 other: mL/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Summary of effects seen by daily gavage of mice with undiluted TEG over the period of organogenesis:
Effect | Dosage (ml/kg) |
|||
0.0 = water control | 0.5 ml/kg | 5.0 ml/kg | 10.0 ml/kg | |
Gestational body weight change, dys 0 - 18 (g)* | 30.90 +/- 7.47 | 29.63 +/- 6.58 | 28.35 +/- 8.44 | 27.59 +/- 6.94 |
Maternal relative kidney weight (%)* | 1.297 +/- 0.109 | 1.319 +/- 0.1290 | 1.353 +/- 0.1032 | 1.384 +/- 0.1435** |
Gravid uterine weight (g)* | 20.729 +/- 6.056 | 20.303 +/- 4.900 | 19.631 +/- 6.057 | 18.562 +/- 4.980 |
All fetuses | 1.429 +/- 0.115 | 1.416 +/- 0.997 | 1.350 +/- 0.066** | 1.303 +/- 0.098*** |
- males | 1.463 +/- 0.114 | 1.442 +/- 0.116 | 1.384 +/- 0.074** | 1.332 +/- 0.106*** |
- females | 1.391 +/- 0.118 | 1.395 +/- 0.092 | 1.321 +/- 0.066** | 1.271 +/- 0.102*** |
* results as mean +/- SD
** p<0.05 (compared to controls)
*** p<0.01 (compared to controls)
Applicant's summary and conclusion
- Conclusions:
- Administration ot triethylene glycol by gavage to pregnant CD-1 mice during organogenesis at 0.0, 0.5, 5.0 or 10.0 mL/kg/day resulted in maternal toxicity at 10.0 mL/kg/day and fetotoxicity at 10.0 and 5.0 mL/kg/day. The A/D ratio (the ratio of the adult lowest observable effect level to the developmental lowest observable effect level) is greater than 1 indicating preferential susceptibility of the developing mouse fetus to triethylene glycol under the conditions of this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.